Close Menu

small cell lung cancer

The study, which showed that the disease may not only result from tobacco exposure as previously thought, could lay the groundwork for targeted therapies.

The transcription-based subtypes could differentiate which SCLC patients respond to treatments, such as immune checkpoint inhibitors and PARP inhibitors.

However, the lack of biomarker-specific treatment data kept researchers from definitively concluding that precision oncology treatments were behind an accelerated rate of NSCLC mortality decline.

The company will test whether ALRN-6924 can protect patients with TP53-mutated small-cell lung cancer from the off-target effects of chemotherapy topotecan.

Researchers performed single-cell RNA sequencing and demonstrated that the emerging heterogeneity in SCLC necessitates optimal combination treatment strategies at the outset.  

Treatment biomarkers for small cell lung cancer have been nearly non-existent, but researchers are beginning to find ones that mark PARP inhibitor response.